JP7793595B2 - 補体因子の阻害剤及びその使用 - Google Patents

補体因子の阻害剤及びその使用

Info

Publication number
JP7793595B2
JP7793595B2 JP2023503413A JP2023503413A JP7793595B2 JP 7793595 B2 JP7793595 B2 JP 7793595B2 JP 2023503413 A JP2023503413 A JP 2023503413A JP 2023503413 A JP2023503413 A JP 2023503413A JP 7793595 B2 JP7793595 B2 JP 7793595B2
Authority
JP
Japan
Prior art keywords
mmol
compound
phenyl
disease
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023503413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534974A (ja
JP2023534974A5 (https=
Inventor
アール． アーティス，ディーン
フィリップ レスリー，コリン
ビアージョ ミレオ，ルカ
ビート，クラウディア
ソラーナ，フェデリコ
ググリエルモ，ブルーノ ディ
パドロニ，キアラ
Original Assignee
アネクソン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アネクソン，インコーポレーテッド filed Critical アネクソン，インコーポレーテッド
Publication of JP2023534974A publication Critical patent/JP2023534974A/ja
Publication of JP2023534974A5 publication Critical patent/JP2023534974A5/ja
Application granted granted Critical
Publication of JP7793595B2 publication Critical patent/JP7793595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023503413A 2020-07-20 2021-07-19 補体因子の阻害剤及びその使用 Active JP7793595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063054064P 2020-07-20 2020-07-20
US63/054,064 2020-07-20
PCT/US2021/042198 WO2022020244A1 (en) 2020-07-20 2021-07-19 Inhibitors of complement factors and uses thereof

Publications (3)

Publication Number Publication Date
JP2023534974A JP2023534974A (ja) 2023-08-15
JP2023534974A5 JP2023534974A5 (https=) 2024-07-26
JP7793595B2 true JP7793595B2 (ja) 2026-01-05

Family

ID=79729495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503413A Active JP7793595B2 (ja) 2020-07-20 2021-07-19 補体因子の阻害剤及びその使用

Country Status (18)

Country Link
US (3) US11814404B2 (https=)
EP (1) EP4185592A4 (https=)
JP (1) JP7793595B2 (https=)
KR (1) KR20230041758A (https=)
CN (2) CN116947903A (https=)
AR (1) AR123011A1 (https=)
AU (1) AU2021311455A1 (https=)
BR (1) BR112023001007A2 (https=)
CA (1) CA3186022A1 (https=)
CL (1) CL2023000191A1 (https=)
CO (1) CO2023000683A2 (https=)
IL (1) IL299840A (https=)
MX (1) MX2023000919A (https=)
PE (1) PE20231435A1 (https=)
PH (1) PH12023550153A1 (https=)
TW (1) TW202216168A (https=)
UY (1) UY39331A (https=)
WO (1) WO2022020244A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022020244A1 (en) 2020-07-20 2022-01-27 Annexon, Inc. Inhibitors of complement factors and uses thereof
IL314164A (en) 2022-01-14 2024-09-01 Annexon Inc Inhibitors of complement factors and their uses
AR131723A1 (es) * 2023-01-30 2025-04-23 5Metis Inc Compuestos que contienen boro y sus usos
WO2024254704A1 (en) * 2023-06-15 2024-12-19 The Governors Of The University Of Alberta Hemiboronic heterocyclic compounds and uses thereof
EP4553080A1 (en) 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Nucleoside derivatives as antiviral agents against coronaviruses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
JP2016526393A (ja) 2013-07-09 2016-09-05 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ抗体及びその使用
JP2018507899A (ja) 2015-03-13 2018-03-22 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
EP1971664B1 (en) * 2006-01-13 2015-09-09 LG Chem, Ltd. Emitting materials and organic light emitting device using the same
KR20100031723A (ko) 2007-07-07 2010-03-24 이데미쓰 고산 가부시키가이샤 크리센 유도체 및 이를 이용한 유기 전계 발광 소자
KR101233377B1 (ko) 2008-12-30 2013-02-18 제일모직주식회사 신규한 유기광전소자용 화합물 및 이를 포함하는 유기광전소자
TWI532741B (zh) 2013-09-04 2016-05-11 喜星素材股份有限公司 含吡唑之多環化合物及使用其之有機發光裝置
KR101635154B1 (ko) 2014-08-28 2016-06-30 (주)더블유에스 피리딜기가 결합된 트리아진 유도체 및 이를 포함한 유기 전계발광 소자
KR102233296B1 (ko) * 2014-11-18 2021-03-29 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
AR103397A1 (es) * 2015-01-13 2017-05-10 Syngenta Participations Ag Oxoborazoles microbicidas
KR101981245B1 (ko) 2015-10-27 2019-05-22 주식회사 엘지화학 고리 화합물 및 이를 포함하는 유기 발광 소자
KR101806464B1 (ko) 2015-11-19 2017-12-07 (주)랩토 피리딜기가 결합된 피리미딘 유도체 및 이를 이용한 유기 전계 발광 소자
KR102496411B1 (ko) 2016-01-06 2023-02-06 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2019240471A1 (ko) 2018-06-11 2019-12-19 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
WO2020032428A1 (ko) * 2018-08-09 2020-02-13 덕산네오룩스 주식회사 유기전기 소자용 화합물을 포함하는 유기전기소자 및 그 전자 장치
CN109574917B (zh) 2018-12-03 2020-12-08 武汉尚赛光电科技有限公司 一种芴酮衍生物及其制备和应用
CN109574910B (zh) * 2018-12-19 2021-07-02 山西大学 一种咔唑衍生物mcab及其制备方法和应用
CN111087387B (zh) 2019-12-26 2022-04-29 厦门天马微电子有限公司 一种有机化合物、显示面板及显示装置
CN111423390A (zh) 2020-03-30 2020-07-17 北京燕化集联光电技术有限公司 一种新型结构化合物及其应用
CN111662309B (zh) 2020-07-10 2021-11-09 北京燕化集联光电技术有限公司 一种多杂环结构化合物及其应用
WO2022020244A1 (en) 2020-07-20 2022-01-27 Annexon, Inc. Inhibitors of complement factors and uses thereof
CN113045585A (zh) 2021-03-16 2021-06-29 吉林奥来德光电材料股份有限公司 一种有机稠环化合物及其制备方法和应用
CN113831332B (zh) 2021-10-29 2024-06-18 长春海谱润斯科技股份有限公司 一种含氮杂环衍生物及其在有机电致发光器件中的应用
IL314164A (en) 2022-01-14 2024-09-01 Annexon Inc Inhibitors of complement factors and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
JP2016526393A (ja) 2013-07-09 2016-09-05 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ抗体及びその使用
JP2018507899A (ja) 2015-03-13 2018-03-22 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med.Chem. Lett. ，2004年，14，3043-3047
blood advances，2018年，2(5)，549-558
Fronties in Immunology，2017年，Vol.8,1115，1-11
Res Pract Thromb Hoemost，2019年，3，599-606

Also Published As

Publication number Publication date
CL2023000191A1 (es) 2023-09-08
US20240109920A1 (en) 2024-04-04
UY39331A (es) 2022-02-25
AU2021311455A1 (en) 2023-02-16
CN116947903A (zh) 2023-10-27
MX2023000919A (es) 2023-04-19
CA3186022A1 (en) 2022-01-27
BR112023001007A2 (pt) 2023-03-28
IL299840A (en) 2023-03-01
PE20231435A1 (es) 2023-09-14
US11814404B2 (en) 2023-11-14
EP4185592A1 (en) 2023-05-31
CO2023000683A2 (es) 2023-01-26
AR123011A1 (es) 2022-10-19
EP4185592A4 (en) 2024-08-21
US12509474B2 (en) 2025-12-30
JP2023534974A (ja) 2023-08-15
KR20230041758A (ko) 2023-03-24
US20220048930A1 (en) 2022-02-17
PH12023550153A1 (en) 2024-03-18
WO2022020244A1 (en) 2022-01-27
US20260070932A1 (en) 2026-03-12
TW202216168A (zh) 2022-05-01
CN116261564A (zh) 2023-06-13

Similar Documents

Publication Publication Date Title
JP7793595B2 (ja) 補体因子の阻害剤及びその使用
ES2467109T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
JP2016512846A (ja) Ｒａｓ阻害剤およびその使用
WO2012125746A1 (en) Tricyclic gyrase inhibitors
WO2013018733A1 (ja) １，５－ナフチリジン誘導体又はその塩
US20160046618A1 (en) Cyclopropyl Fused Thiazin-2-Amine Compounds as Beta-Secretase Inhibitors and Methods of Use
JP2018525372A (ja) 呼吸器合胞体ウイルス阻害剤
KR20180072665A (ko) 안트라센-9,10-디온 디옥심 화합물 전구약물 및 이의 용도
TWI600644B (zh) 二甲基吡啶胺衍生物及其醫藥用途
WO2024008909A1 (en) Inhibitors of coronavirus
KR20250070082A (ko) 헤테로사이클릭 sik 억제제
CA3118488A1 (en) Chemical compounds
US11649255B2 (en) Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same
CA3259338A1 (en) ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2025502254A (ja) 補体因子の阻害剤及びその使用
EP4400493A1 (en) Hydroxamic acid compound having enpp1 inhibitory activity and use thereof
HK40096479A (zh) 补体因子的抑制剂和其用途
WO2017198159A1 (zh) 含桥环的咪唑衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230426

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240718

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251217

R150 Certificate of patent or registration of utility model

Ref document number: 7793595

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150